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The predictive testing (PST) model for late-onset 
neurodegenerative diseases such as Huntington’s disease (HD), a 
rare disorder with a prevalence of ~1-7 in 100,000 individuals of 
European ancestry (Ramos et al., 2015), has been implemented and 
adapted for other late-onset diseases around the world (Hawkins, 
Ho, & Hayden, 2011), namely, Machado-Joseph disease (MJD) 
and Familial Amyloidotic Polyneuropathy (FAP), two Portuguese 
monogenic, autosomal and dominant diseases (Sequeiros et al., 
2006), with a severe neurodegenerative evolution and no effective 
cure. In Continental Portugal, MJD has a prevalence of 1: 100,000, 
and is considered a rare disease, except for the area of the Tejo 
Valley (1: 1000) (Bettencourt & Lima, 2011); signs of cerebellar 
ataxia, progressive external ophthalmoplegia and pyramidal signs 
are reported (Coutinho, 1996; Sequeiros et al., 2006). Although 
Amyloidosis is very rare (less than 1 case in 100,000 people 
worldwide) it is more frequent in some countries such as Portugal, 
wherein the Val30Met mutation occurs in 1 in 1,000 people in 
areas of higher incidence like Póvoa Varzim/Vila do Conde, 
the most likely focus of origin of the disease (with 1/3 of total 
Portuguese patients). Sousa (1995) described a disease prevalence 
of 90.3/100,000 and an average age of onset of 33.5 years. For 
FAP, an abnormal amyloid protein (TTR) is deposited in various 
organs leading patients to experience progressive limitations 
(Saraiva, 1986). 
There are several studies about the PST psychosocial short-term 
impact (one year) that did not demonstrate a severe negative impact 
(Lêdo, Leite, & Sequeiros, 2013; Lêdo, Paneque, Rocha, Leite, 
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Abstract Resumen
Background: Over the past 20 years, studies have revealed that the 
communication of a pre-symptomatic test (PST) result for late-onset 
diseases, such as Huntington’s disease (HD), doesn’t cause psychological 
disturbance. This cross-sectional study investigated the middle- (4 years) 
to long-term (7 and 10 years) psychological impact of PST for 3 autosomal 
dominant late-onset diseases: HD, Machado-Joseph disease (DMJ) and 
familial amyloid polyneuropathy (FAP). Method: The study included 203 
subjects: 170 (84%) agreed to make the PST for FAP, 29 (14%) for HD and 
4 (2%) for MJD. They were mostly women (58%) and married (67%). It was 
considered the cutoffs points: 4 years (middle-term) and 7 and 10 years 
(long-term) indicating the time after receiving the TPS results. Results: 
women and widows (oldest) presented the highest mean values for almost 
all BSI dimensions and the highest values correspond to the obsessive-
compulsive dimension. MJD participants presented the highest mean 
values. No differences were found concerning the PST test results while 
participants are still asymptomatic. Psychopathology was only present in 
symptomatic carriers. Conclusions: The onset of the disease seems to 
assume the trigger for psychological disturbance, regardless the time that 
has elapsed since the PST result communication or the individual carrier/
non-carrier condition. 
Keywords: Pre-symptomatic testing, psychological impact, late-onset 
genetic diseases.
Pruebas pre-sintomáticas de enfermedades neurodegenerativas: el 
impacto psicopatológico a largo plazo. Antecedentes: el presente 
estudio transversal investigó el impacto psicopatológico a medio (4 
años) y a largo plazo (7 y 10 años) de la prueba pre-sintomática (PPS) 
para tres enfermedades autosómicas dominantes de aparición tardía: 
enfermedad de Huntington EH, la enfermedad de Machado-Joseph (EMJ) 
y la polineuropatía amiloide familiar (PAF). Método: participaron 203 
sujetos: 170 (84 %) realizaron el PPS para PAF, 29 (14 %) para EH y 4 (2 
%) para EMJ. La muestra, en su mayoría, estuvo compuesta por mujeres 
(58 %) y por personas casadas (67 %). Fueron considerados como puntos 
de corte los 4, 7 y 10 años después de haber recibido el resultado de la 
PPS. Resultados: las mujeres y los viudos presentan las medias más altas. 
Los participantes con EMJ presentaron las medias más elevadas. No se 
encontraron diferencias signifi cativas en lo concerniente a los resultados 
de PPS. La perturbación psicológica fue escasamente observada en los 
sujetos portadores que ya evidenciaban síntomas. Conclusiones: la 
aparición de los primeros síntomas parece constituir el detonante para 
la existencia de perturbaciones psicológicas, independientemente del 
intervalo de tiempo sucedido desde la comunicación de los resultados de 
la PPS o de la condición genética (portador/no portador). 
Palabras clave: prueba pre-sintomática, impacto psicopatológico, 
enfermedades genéticas de aparición tardía.
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& Sequeiros, 2013; Rolim et al., 2006; Tibben, 2007). However, 
there are few studies investigating the PST psychosocial impact in 
the mid- to long-term (Almqvist et al., 2003; Decruyenaere et al., 
2003; Decruyenaere et al., 2004; Gargiulo et al., 2009; Gonzalez 
et al., 2012; Timman, Roos, Maat-Kievit, & Tibben, 2004).
At the Center for Predictive and Preventive Genetics (CGPP), 
Institute of Molecular and Cell Biology (IBMC), University of Porto 
(Portugal), a national reference model was developed for one year 
of genetic counseling protocol for individuals at-risk for HD, MJD 
and FAP (Rolim et al., 2006). Lêdo and colleagues (2013) studied 
the psychopathological impact on this population a year after the 
PST protocol and noticed that values decreased signifi cantly one 
year after the implementation of the PST, regardless of the disease 
studied or the test result; however, for all Brief Symptom Inventory 
(BSI) dimensions and global indexes, signifi cantly higher values 
were found than those of control groups. Therefore, it became a 
priority to study the mid- to long-term PST psychological impact 
as a result of communicating the genetic status to subjects that 
underwent the PST, and compare the results obtained with those of 
the few studies for HD (Decruyenaere et al., 2003; Decruyenaere 
et al., 2004; Gargiulo et al., 2009; Timman et al., 2004). The main 
aim of this research is to increase the knowledge about follow-
up studies investigating the long-term consequences of PST, as 
suggested by Timman and colleagues (2004) so that the adjustment 
of psychological support for this population may be possible in the 
context of the Portuguese reality. 
Method
This research is a descriptive cross-sectional study, resulting from 
the compilation of the medical records of the subjects who completed 
the one year PST protocol at CGPP (including the molecular study) 
and discovered their genetic status at least three years ago, for three 
autosomal dominant late-onset conditions: HD, MJD and FAP. 
Participants
Fifty eight percent of subjects were female and the majority of 
the responses correspond to age ranging up to 30 years [21-77]. 
The majority of subjects had mainly professions involving some 
responsibilities (1st Graffar Index) and a high level of education. 
Most of the subjects underwent the PST for FAP (84%) and 37% 
were identifi ed as carriers; of these, 15% had become symptomatic 
and 5% having had a liver transplant (Table 1). 
Out of the 203 subjects, 32% had been informed about their 
genetic status 4 years ago (middle-term), 47% 7 years ago and 21% 
10 years ago (the long-term). Concerning the three different cutoff 
points, data were similar to data observed in the total sample, with 
the exception of those subjects who completed the protocol 10 
years ago, where the age increases (31-40 years) and, consequently, 
raising the number of pensioners. Those subjects, who underwent 
the PST protocol 7 years ago, present the highest mean age and 
many of them are already retired.
Instruments
The socio-demographic data - gender, age, profession, and 
current marital status - were collected from a questionnaire sent 
to all participants. The questionnaire sent to carriers also included 
the following questions (clinical variables) “Current clinical 
status”, “Still without symptoms?”, and “Had a signifi cant change 
in your life in recent years?”. No clinical variables were included 
in the questionnaire to non-carriers.
The dependent variable psychopathology was assessed using 
the BSI (Derogatis, 1993) adapted for the Portuguese population by 
Canavarro (2007). This instrument is composed of 53 items, rated 
on a Likert scale of fi ve grades (0 “rarely” to 4 “very often”), nine 
dimensions and three global indexes which express psychometric 
ratings of emotional distress: global severity index (GSI), positive 
symptoms total (PSTI) and positive symptom distress index (PSDI). 
Procedure
This study was accepted by the IBMC ethics committee. 
Information about the researcher, the nature and objectives of the 
study and the principle of confi dentiality was displayed when the 
subjects were originally registered in the PST protocol. Participants 
were contacted by mail in order to answer the questionnaire that 
included sociodemographic and clinical data and the BSI.
Data analysis 
The statistical analysis was performed using the PASW 
Statistics Program, version 22.0. Descriptive [frequencies (N 
Table 1
Sample description 
Frequencies
(N = 203)
Percentage
(100%)
Gender
Female
Male
118
85
58.1
41.9
Age
≤ 30 years
31 - 40 years
41- 50 years
51 - 60 years
61 - 70 years
≥ 71 years
88
62
20
22
8
3
43.3
30.5
9.9
10.8
3.9
1.5
Marital Status 
Single
Married
Divorced
Widow
53
132
10
3
26.6
66.5
5.0
1.5
Profession
Retired
Unemployed
Student
1St Graffar Index
2nd Graffar Index
3rd Graffar Index
4th Graffar Index
5th Graffar Index
40
19
15
59
11
4
22
33
19.7
9.4
7.4
29.1
5.4
2.0
10.8
16.3
Type of Disease
HD
MJD
FAP
29
4
170
14.3
2.0
83.7
PST Result
Non-carrier
Carrier
91
112
44.8
55.2
Clinical Status 
Non-carrier
Asymptomatic Carrier 
Symptomatic Carrier
Liver Transplanted 
(FAP carriers)
89
73
29
9
44.5
36.5
14.5
4.5
Note: PST=Pre-symptomatic Testing
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and n), mean (M) and standard deviation (SD)] and inferential 
[bi-variate statistical (ANOVA, chi-square test and bi-varying 
correlation)] analyses were carried out.
Results
BSI descriptive analysis 
When considering the three cutoff points of 4, 7 and 10 years, 
mean and standard deviation were very similar to the ones relating 
to BSI scores (Table 2). For the three cutoff points, α was similarly 
high, pointing to a good scale reliability. Comparisons of means 
were performed but no statistically signifi cant differences were 
found. 
Comparison between the BSI means regarding independent 
variables
Analyzing the mean values for the BSI variables, regarding 
socio-demographic and clinical variables, some statistically 
signifi cant results were found: 
Socio-demographic variables
Gender variable. Female presented higher mean values than 
men for the BSI total scores and for BSI somatization, interpersonal 
sensitivity, depression and phobic anxiety dimensions. The 
mean values for GSI and PSTI revealed statistically signifi cant 
differences (Table 3). 
Age variable. Signifi cant results were found in the obsessive-
compulsive dimension - F (5, 189) = 2.325, p = .045; η2 = .058 - and 
in the PSTI – F (5, 189) = 2.551,  p = .029; η2 = .066 -, meaning that 
mean age and values increase in a similar direction. The exception 
occurred with older subjects that presented the lower averages for 
the same obsessive-compulsive dimension, M
≤30 
(n = 88) = 4.71; 
M
31-40 
(n = 62) = 5.71; M
41-50 
(n = 20) = 6.22; M
51-60 
(n = 22) = 7.00; 
M
61-70 
(n = 8) = 9.29; M
≥71 
(n = 3) = 4.33. The same trend is verifi ed 
for the PSTI - M
≤30 
(n = 88) = 21.24; M
31-40 
(n = 62) = 22.37; M
41-50 
(n = 20) = 22.20; M
51-60 
(n = 22) = 23.73; M
61-70 
(n = 8) = 21.75; M
≥71 
(n = 3) = 13.67.
Marital status variable. Widows presented signifi cantly lower 
mean values for almost all dimensions than single, married and 
divorced subjects; and divorced subjects the highest for all the BSI 
dimensions (Table 4).
Clinical variables
Type of disease. Phobic anxiety [F (2, 192) = 9.434, p = .000; η2= 
.091], psychoticism [F (2, 192) = 3.958, p = .021; η2 = .040] and PSDI 
values [F (2, 192) = 5.170, p = .007; η2 = .054] presented signifi cant 
differences. MJD subjects showed higher mean values than FAP 
and HD subjects, regarding phobic anxiety [M
HD 
(n = 29) = 1.15; 
M
MJD 
(n = 4) = 7.50; M
FAP 
(n = 170) = 1.70], psychoticism [M
HD 
(n = 
29) = 2.35; M
MJD 
(n = 4) = 6.75; M
FAP 
(n = 170) = 2.34] and PSDI [M
HD 
(n = 29)
 
= 1.47; M
MJD 
(n = 4) = 2.27; M
FAP 
(n = 170) = 1.44]. 
PST results variable. Signifi cant differences were found in 
somatization [F (1, 193) = 6.035,  p = .015; η2 = .029] and PSDI [F 
(1, 193) = 4.569,  p = .034; η2 = .021], where carriers (c) showed 
higher mean values than non-carriers (nc): somatization: M
c 
(n = 
112) = 4.78 and M
nc 
(n = 91) = 3.14; PSDI: M
c 
(n = 112) = 1.52 and 
M
nc 
(n = 91) = 1.37. Current clinical status variable. Statistical 
signifi cant values were found in somatization [F (3, 189) = 7.451, 
p = .000; η2 = .104] and PSTI [F (3, 189) = 3.269, p = .023; η2 = 
.048]. Non-carriers [M (n = 89) = 3.14] and asymptomatic carriers 
[M (n = 73) = 3.58] had lower mean values than symptomatic 
carriers [M (n = 29) = 7.63] and, in FAP disease, liver transplanted 
subjects [M (n = 9) = 5.43]. For PSTI, non-carriers [M (n = 89) 
= 21.72], asymptomatic carriers [M (n = 29) = 20.55] and liver 
transplanted carriers [M (n = 9) = 17.44] presented lower mean 
values than symptomatic carriers [M (n = 29) = 27.00]. 
“Still without symptoms?” variable. In the carriers group, 
signifi cant differences were found for all BSI dimensions and GSI, 
PSTI and PSDI, except for the phobic anxiety dimension (Table 
5): subjects who still had no symptoms had lower mean values 
than those who already had symptoms; subjects that answered 
“perhaps” were those with the highest mean values. Carriers that 
answered “no” (n = 30) or “perhaps” (n = 9) presented signifi cant 
differences for somatization [F (3, 189) = 3.966, p = .016; η2 = 
.218].
Subjects that considered having severe [M (n = 11) = 11.33] 
and moderate [M (n = 7) = 10.86] symptoms had higher means in 
somatization than those subjects that present minimal symptoms 
Table 2
BSI total, nine dimensions and three indexes (M, SD and α) at the cutoff points 
of 4, 7 and 10 years
4 years
(n = 65)
7 years
(n = 95)
10 years
(n = 42)
   M SD   M SD  M SD
(α) (α) (α)
BSI Total 
36.28 33.72 36.65 28.24 31.32 24.41
(.97) (.97) (.96)
Somatization  
4.15 5.28 4.39 4.67 3.01 3.51
(.88) (.87) (.80)
Obsessive-compulsive  
5.42 4.71 5.85 4.49 5.13 3.79
(.86) (.87) (.77)
Interpersonal sensitivity  
2.72 2.82 2.97 2.61 2.55 2.45
(.80) (.79) (.78)
Depression  
4.58 4.97 4.53 4.49 3.25 3.00
(.88) (.89) (.77)
Anxiety  
3.75 4.19 3.96 3.37 3.61 3.27
(.84) (.78) (.84)
Hostility  
3.97 3.85 4.15 3.47 3.30 2.70
(.85) (.86) (.75)
Phobic anxiety  
1.68 3.31 1.62 2.55 2.00 2.75
(.85) (.77) (.67)
Paranoid ideation  
4.49 4.38 4.54 3.76 4.40 3.41
(.84) (.83) (.76)
Psychoticism  
2.72 3.42 2.51 3.21 1.90 2.48
(.75) (.82) (.77)
GSI 0.68 0.64 0.69 0.53 0.59 0.46
PSTI 21.02 14.19 23.00 14.87 20.10 12.43
PSDI 1.55 0.53 1.42 0.44 1.41 0.37
Note: BSI = Brief Symptom Inventory; GSI = Global Severity Index; PSTI = Positive 
Symptoms Total Index; PSDI = Positive Symptom Distress Index; M = Mean; SD = 
Standard deviation; α = Cronbach’s alpha
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Table 3
Comparison of means for the gender variable: BSI total, four dimensions and two indexes (M, F, df, p and η2)
n      M (SD) F df p η2
BSI Total 
Female (118)
Male (85)
39.48 (33.01)
29.87 (22.37)
5.007 1, 193   .026 .026
Somatization  
Female (118)
Male (85)
4.81 (5.24)
2.99 (3.48)
7.397 1, 193   .007   .037
Interpersonal sensitivity  
Female (118)
Male (85)
3.13 (2.77)
2.33 (2.36)
4.480 1, 193   .036   .023
Depression  
Female (118)
Male (85)
4.91 (4.70)
3.40 (3.80)
5.701 1, 193   .018   .029
Phobic anxiety  
Female (118)
Male (85)
2.17 (3.31)
1.11 (1.89)
6.596 1, 193   .011   .033
GSI
Female (118)
Male (85)
0.75 (0.62)
0.56 (0.42)
5.007 1, 193   .026   .026
PSTI
Female (118)
Male (85)
23.55 (14.70)
19.51 (13.19)
4.070 1, 193   .045   .020
Note: BSI = Brief Symptom Inventory; GSI = Global Severity Index; PSTI = Positive Symptoms Total Index; M = Mean; F = Snedecor’s F Distribution; df = degrees of freedom; p = p-value; 
η2 = effect size
Table 4
Comparison of means for marital status variable: BSI total, six dimensions and one index (M, F, df, p and η2)
n      M (SD) F df p η2
BSI Total
Single (104)
Married (89)
Divorced (5)
Widow (2)
29.36 (25.44)
36.85 (28.71)
62.22 (50.43)
15.67 (2.89)
3.899 3 .010 .060
Somatization 
Single (104)
Married (89)
Divorced (5)
Widow (2)
2.60 (3.55)
4.51 (4.54)
7.33 (9.30)
1.00 (1.73)
4.169 3 .007 .066
Obsessive-compulsive  
Single (104)
Married (89)
Divorced (5)
Widow (2)
4.66 (3.14)
5.60 (4.46)
10.22 (7.98)
5.67 (0.58)
4.235 3  .006  .064
Depression  
Single (104)
Married (89)
Divorced (5)
Widow (2)
4.11 (4.41)
4.09 (4.13)
9.11 (6.72)
2.00 (0.00)
4.121 3  .007  .062
Anxiety  
Single (104)
Married (89)
Divorced (5)
Widow (2)
3.38 (3.17)
3.90 (3.55)
6.78 (6.57)
1.33 (0.58)
2.762 3  .043  .043
Phobic anxiety  
Single (104)
Married (89)
Divorced (5)
Widow (2)
0.68 (1.17)
2.10 (3.12)
3.56 (4.53)
0.33 (0.58)
4.789 3  .003  .073
Paranoid ideation  
Single (104)
Married (89)
Divorced (5)
Widow (2)
3.49 (3.21)
4.80 (3.92)
7.33 (5.92)
1.33 (1.15)
3.820 3  .011  .058
GSI
Single (104)
Married (89)
Divorced (5)
Widow (2)
0.55 (0.48)
0.69 (0.54)
1.17 (0.95)
0.29 (0.54)
3.899 3  .010  .060
Note: BSI = Brief Symptom Inventory; GSI = Global Severity Index; M = Mean; F = Snedecor’s F Distribution; df = degrees of freedom; p = p-value; η2 = effect size
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[M (n = 16) = 5.73] and those who didn’t specifi ed their symptoms 
in the questionnaire (n = 5). 
“Has there been a signifi cant change in your life (marriage, 
divorce, death of loved one, illness, job change, earth, etc.) in 
recent years?” variable. Signifi cant differences were found 
concerning somatization, depression, anxiety and hostility 
dimensions and GSI and PSTI, emphasizing that carriers who 
experienced meaningful life changes presented higher mean 
values than those that did not (Table 6).
Discussion
This study does not corroborate previous studies suggesting 
the absence of negative psychological impact resulting from 
the PST long-term outcome (Timman et al., 2004), because the 
BSI dimensions values obtained in this sample were higher than 
those obtained in previous studies about short-term psychological 
impact (Lêdo et al., 2013b) and when compared with the standard 
values reached for the Portuguese population. Nevertheless, 
and regarding the GSI, PSTI and PSDI, the obtained values did 
not refl ect the presence of clinically psychological disturbance 
since the PSDI was always inferior to 1.7 (Canavarro, 2007). 
The lower GSI, PSTI and PSDI scores may be justifi ed by the 
existence of a self-selection prior to PST of those subjects who 
were psychologically more prepared (Codori et al., 1994; Paneque 
et al., 2007; Rolim et al., 2006; Tibben, 2007) and that could be 
the same who responded to the present study. Subjects who were 
less psychological disturbed prior to the PST were those who did 
not drop out of the follow-ups or did not avoid the reality of the 
disease (Timman et al., 2004). 
Age variable and the obsessive-compulsive dimension 
presented a positive correlation. This may be explained due to 
Table 5
Comparison of means for the variable “Still without symptoms?”: BSI total, eight dimensions and three indexes (M, F, df, p and η2)
                                          n      M (SD) F df p η2
BSI Total 
Yes (67)
Perhaps (9)
No (30)
29.62 (25.76)
67.22 (35.09)
44.92 (33.97)
8.042 2  .001  .142
Somatization  
Yes (67)
Perhaps (9)
No (30)
3.06 (4.22)
10.44 (6.60)
7.00 (5.20)
13.925 2  .000  .218
Obsessive-compulsive  
Yes (67)
Perhaps (9)
No (30)
4.88 (4.20)
9.89 (5.03)
6.48 (5.24)
5.264 2  .007  .095
Interpersonal sensitivity  
Yes (67)
Perhaps (9)
No (30)
2.43 (2.26)
5.44 (2.65)
3.19 (3.10)
5.823 2  .004  .104
Depression  
Yes (67)
Perhaps (9)
No (30)
3.40 (3.75)
7.56 (4.59)
5.44 (4.88)
5.377 2  .006  .097
Anxiety  
Yes (67)
Perhaps (9)
No (30)
3.24 (3.30)
6.33 (3.81)
5.11 (4.14)
4.682 2  .011  .086
Hostility  
Yes (67)
Perhaps (9)
No (30)
3.51 (3.56)
7.56 (5.66)
5.07 (4.28)
4.888 2  .009  .089
Paranoid ideation  
Yes (67)
Perhaps (9)
No (30)
3.66 (3.35)
6.56 (5.68) 
5.48 (4.40)
3.675 2  .029  .068
Psychoticism  
Yes (67)
Perhaps (9)
No (30)
1.75 (2.45)
4.89 (4.57)
3.31 (4.13)
5.293 2  .007  .097
GSI
Yes (67)
Perhaps (9)
No (30)
0.56 (0.49)
1.27 (0.66)
0.85 (0.64)
8.042 2  .001  .142
PSTI
Yes (67)
Perhaps (9)
No (30)
19.61 (12.81)
35.89 (10.09)
23.90 (15.99)
6.002 2  .003  .104
PSDI
Yes (67)
Perhaps (9)
No (30)
1.41 (0.45)
1.81 (0.65)
1.67 (0.51)
4.453 2  .014  .085
Note: BSI = Brief Symptom Inventory; GSI = Global Severity Index; PSTI = Positive Symptoms Total Index; PSDI = Positive Symptom Distress Index; M = Mean; F = Snedecor’s F Distribution; 
df = degrees of freedom; p = p-value; η2 = effect size
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a progressive concern with the outbreak of the fi rst symptoms, 
as suggested by Licklederer, Wolff and Barth (2008). Divorced 
subjects were those who presented the highest values in almost 
all BSI dimensions and widows the lowest: that points to the 
importance of the real/imaginary experiences of rejection/
abandonment as realities that might be interfering with these 
results, instead of the real experiences of loss or feelings of 
loneliness that might be present with the widowhood (Lêdo et 
al., 2013b). 
Subjects who underwent PST for MJD presented the highest 
values in psychoticism and phobic anxiety maybe because 
MJD patients have shown some emotional changes related to 
disruption of frontal-subcortical systems (Zawacki, Grace, 
Friedman, & Sudarsky, 2002) and cognitive disorders (Rezende 
et al., 2015); although  the MJD sample dimension is very small 
and a previous study conducted with subjects at-risk for MJD 
showed no psychological disturbance at post-test and after they 
knew their carriers/non-carriers status (Gonzalez et al., 2004). 
Additionally, FAP group is aware of a therapeutic solution that 
prevents progression of the disease to an advanced state (Coelho, 
Maia, Martins da Silva, Waddington, Planté-Bordeneuve, Lozeron 
et al., 2012). 
All carriers had the highest values in somatization and PSDI, 
what is understandable since the carrier condition leads them to 
be more focused on their physical and body sensations, suggesting 
that higher levels of somatization are associated with real 
symptoms. The presence of real symptoms appeared to increase 
the tendency for these individuals to report somatic reactions 
(Lêdo, Leite, Souto, Dinis, & Sequeiros, 2016; Licklederer et al., 
2008), although the perspective that they may probably already 
have symptoms let them more disturbed than the certainty of 
having symptoms (Licklederer et al., 2008). 
Subjects who had signifi cant changes in their lives were those 
who presented higher values in somatization, anxiety and hostility 
dimensions. Being one of the mentioned changes reported the 
“loss or illness of a close relative” item, it explains the high values 
on the referred dimensions (Lêdo et al., 2016).
Although the results did not present differences between the 
psychological impact in the mid- to long-term, they suggest that 
this impact exists but without being possible to differentiate it 
regarding the time resulting from the completion and notifi cation 
of the PST result. So, the age of symptoms onset was not recognized 
as being determinant to the level of psychological disturbance 
(Lêdo et al., 2016; Licklederer et al., 2008).
Table 6
Comparison of means for the variable “Has there been a signifi cant change in your life in recent years?”: BSI total, four dimensions and two indexes (M, F, df, p and η2)
n M (SD) F df p η2
BSI Total 
No (54)
Yes (56)
29.27 (27.43)
45.77 (33.09)
7.631 1  .007  .070
Somatization  
No (54)
Yes (56)
3.58 (4.39)
5.94 (5.76)
5.666 1  .019  .051
Depression  
No (54)
Yes (56)
3.34 (3.97)
5.61 (4.87)
6.991 1  .009  .062
Anxiety  
No (54)
Yes (56)
3.00 (3.25)
5.21 (3.98)
9.798 1  .002  .086
Hostility  
No (54)
Yes (56)
3.49 (3.68)
5.15 (4.34)
4.528 1  .036  .041
GSI
No (54)
Yes (56)
0.55 (0.52)
0.86 (0.62)
7.631 1  .007  .070
PSTI
No (54)
Yes (56)
19.41 (13.13)
25.66 (15.15)
5.334 1  .023  .047
Note: BSI = Brief Symptom Inventory; GSI = Global Severity Index; PSTI = Positive Symptoms Total Index; M = Mean; F = Snedecor’s F Distribution; df = degrees of freedom; p = p-value; 
η2 = effect size
References
Almqvist, E. W., Bloch, M., & Hayden, M. (1999). A worldwide 
assessment of the frequency of suicide, suicide attempts, or psychiatric 
hospitalization after predictive testing for Huntington Disease. 
American Journal of Human Genetics, 64, 1293-1304. 
Almqvist, E. W., Brinkman, R. R., Wiggins, S., & Hayden, M. R. (2003). Canadian 
collaborative study of predictive testing. Psychological consequences and 
predictors of adverse events in the fi rst 5 years after predictive testing for 
Huntington’s disease. Clinical Genetics, 64, 300-309. 
Bettencourt, C., & Lima, M. (2011). Machado-Joseph disease: From fi rst 
descriptions to new perspectives. Orphanet Journal of Rare Diseases, 
2, 35-35.
Bloch, M., Fahy, M., Fox, S., & Hayden, M. (1989). Presymptomatic testing 
for Huntington disease: II.  Demographic characteristics, life-style 
patterns, attitudes, and psychosocial assessments of the fi rst fi fty-one 
test candidates. American Journal of Medical Genetics, 32, 217-224.
Canavarro, C. (2007). Inventário de Sintomas Psicopatológicos (BSI). Uma 
revisão crítica dos estudos realizados em Portugal [Brief Symptom 
Inventory (BSI). A critical review of the studies carried out in Portugal]. 
In M. Simões, C. Machado, M. Gonçalves, L. Almeida (Eds), Avaliação 
Psicológica. Instrumentos validados para a população portuguesa 
[Psychological evaluation. Instruments validated for the Portuguese 
population] (vol. III, pp. 305-331). Portugal: Quarteto Editora.
Susana Lêdo, Ângela Leite, Teresa Souto, Maria Alzira Pimenta Dinis and Jorge Sequeiros
452
Codori, A. M., Hanson, R., & Brandt, J. (1994). Self-selection in predictive 
testing for Huntington’s disease. American Journal of Medical 
Genetics, 54, 167-173.
Codori, A., Slavney, P. R., & Brandt, J. (1997). Predictors of psychological 
adjustment to genetic testing of Huntington’s Disease. Health 
Psychology, 16, 36-50.
Coelho, T., Maia, L. F., Martins da Silva, A., Waddington, M., Planté-
Bordeneuve, V., Lozeron, …, Grogan, D. R. (2012). Tafamidis for 
transthyretin familial amyloid polyneuropathy: A randomized, 
controlled trial. Neurology, 79, 785-792.
Decruyenaere, M., Evers-Kiebooms, G., & Van Den Berghe, H. (1997). 
Non-participation in predictive testing for Huntington’s Disease: 
Individual decision-making, personality and avoidant behaviour in the 
family. European Journal of Human Genetics, 5, 351-363.
Decruyenaere, M., Evers-Kiebooms, G., Cloostermans, T., Boogaerts, 
A., Demyttenaere, K., Dom, R., & Fryns, J. P. (2003). Psychological 
distress in the 5-year period after predictive testing for Huntington’s 
disease. European Journal of Human Genetics, 11, 30-38.
Decruyenaere, M., Evers-Kiebooms, G., Cloostermans, T., Boogaerts, A., 
Demyttenaere, K., Dom, R., & Fryns, J. P. (2004). Predictive testing for 
Huntington’s disease: Relationship with partners after testing. Clinical 
Genetics, 65, 24-31.
Derogatis, L. R. (1993). BSI: Brief Symptom Inventory. Minneapolis: 
Nacional Computers Systems. 
DudokdeWit, A. C., Tibben, A., Duivenvoorden, H. J., Niermeijer, M. 
F., & Passchier, J. (1998). Predicting adaptation to presymptomatic 
DNA testing for late onset disorders: who will experience distress? 
Rotterdam Leiden Genetics Workgroup. Journal of Medical Genetics, 
35, 745-754.
Gargiulo, M., Lejeune, S., Tanguy, M., Lahlou-Laforet, K., Faudet, A., 
Cohen, D., Feingold, J., & Durr, A. (2009). Long-term outcome of 
presymptomatic testing in Huntington disease. European Journal of 
Human Genetics, 17, 165-171.
Gonzalez, C., Lima, M., Kay, T., Silva, C., Santos, C., & Santos, J. (2004). 
Short-term psychological impact of predictive testing for Machado-
Joseph disease: Depression and anxiety levels in individuals at risk 
from the Azores (Portugal). Community Genetics, 7, 196-201.
Gonzalez, C., Gomes, E., Kazachkova, N., Bettencourt, C., Raposo, 
M., Taylor, T., MacLeod, P., Vasconcelos, J., & Lima, M. (2012). 
Psychological well-being and family satisfaction levels fi ve years after 
being confi rmed as a carrier of the Machado-Joseph disease mutation. 
Genetic Testing and Molecular Biomarkers, 16, 1-6.
Hawkins, A., Ho, A., & Hayden, M. (2011). Lessons from predictive testing 
for Huntington disease: 25 years on. Journal of Medical Genetics, 48, 
649-650. 
International Huntington Association and World Federation of Neurology 
Research Group on Huntington’s Disease (1994). Guidelines for the 
molecular genetics predictive test in Huntington’s disease. Journal of 
Medical Genetics, 31, 555-559.
Lêdo, S. (2002). O primeiro dia do resto de suas vidas. Alguns aspectos 
psicológicos da Paramiloidose [The fi rst day of the rest of their lives. 
Some psychological aspects of Paramyloidosis]. MSc Dissertation, 
ISPA - Lisbon, Portugal.
Lêdo, S., Leite, A., & Sequeiros, J. (2013a). Anxiety and pre-symptomatic 
testing for neurodegenerative disorders. Open Journal of Genetics, 3, 
14-26.
Lêdo, S., Leite, A., Souto, T., Dinis, M. A., & Sequeiros, J. (2016). Middle- 
and long-term anxiety levels resulting from presymptomatic testing of 
HD, MJD and FAP neurodegenerative diseases. Revista Brasileira de 
Psiquiatria, 38, 113-120.
Lêdo, S., Paneque, M., Rocha, J., Leite, A., & Sequeiros, J. (2013b). 
Predictive testing for two neurodegenerative disorders (FAP and HD): 
A psychological point of view. Open Journal of Genetics, 3, 270-279.
Leite, A. (2006). Determinantes Psicossociais da Adesão ao Teste Pré-
Sintomático em Doenças Neurológicas Hereditárias de Aparecimento 
Tardio [Psychosocial Determinants of Adhesion to Pre-Symptomatic 
Testing in Late-Onset Hereditary Neurological Diseases]. PhD 
Dissertation, University of Porto - Porto, Portugal.
Lerman, C. (1997). Psychological aspects of genetic testing: Introduction 
to the special issue. Health Psychology, 16, 3-7.
Licklederer, C., Wolff, G., & Barth, J. (2008). Mental health and quality 
of life after genetic testing for Huntington disease: A long-term effect 
study in Germany. American Journal of Medical Genetics, 146A, 
2078-2085.
Lopes, A., & Fleming, M. (1996). Doença somática e organização psíquica: 
refl exões a partir da Polineuropatia Amiloidótica Familiar [Somatic 
illness and psychic organization: refl ections from Familial Amyloid 
Polyneuropathy]. Revista Portuguesa de Psicanálise, 15, 93-100.
Lopes, A., & Fleming, M. (1998). Aspectos psicológicos da Polineuropatia 
Amiloidótica Familiar: a trama subterrânea intergeracional 
[Psychological aspects of Familial Amyloid Polyneuropathy: The 
intergenerational underground]. Brotéria Genética, XIX, 183-192.
Paneque, H. M., Prieto, A. L., Reynaldo, R. R., Cruz, M. T., Santos, 
F. N., Almaguer, M. L., et al. (2007). Psychological aspects of 
presymptomatic diagnosis of spinocerebellar Ataxia type 2 in Cuba. 
Community Genetics, 10, 132-139.
Paneque, M., Lemos, C., Sousa, A., Velázquez, P. L., Fleming, M., & 
Sequeiros, J. (2009). Role of the disease in the psychological impact of 
pre-symptomatic testing for SCA2 and FAP ATTRV30M: Experience 
with the disease, kinship and gender of the transmitting parent. Journal 
of Genetic Counseling, 18, 483-493.
Rezende, T. J., D’Abreu, A., Guimarães, R. P., Lopes, T. M., Lopes-Cendes, 
I., Cendes, F., Castellano, G., França, & M. C. Jr. (2014). Cerebral 
cortex involvement in Machado-Joseph disease. European Journal of 
Neurology, 22, 277-283. 
Rolim, L., Leite, A., Lêdo, S., Paneque, M., Sequeiros, J., & Fleming, 
M. (2006). Psychological aspects of pre-symptomatic testing for 
Machado-Joseph disease and familial amyloid polyneuropathy type I. 
Journal of Clinical Genetics, 69, 297-305.
Saraiva, M. J., & Costa, P. (1986). Familial Amyloidotic Polyneuropathy, 
Portuguese type: Phenotype and genotype. In M. L. Sales-Luís (Eds.), 
Symposium on Peripheral Neuropathies (pp. 207-212). Lisboa.
Sequeiros, J. (1998). Prenatal diagnosis of late-onset diseases. Progresos 
en Diagnostico Prenatal, 10, 218-220.
Sequeiros, J., Pinto-Basto, J., Rocha, J., Lêdo, S., Leite, A., Rolim, L., …, 
Fleming, M. (2006). Ten years of a programme for presymptomatic 
testing (PST) and prenatal diagnosis (PND) in late-onset neurological 
diseases in Portugal: Machado-Joseph disease (MJD), Huntington 
disease (HD) and familial amyloid neuropathy type I - ATTRV30M 
(FAP-I). European journal of Human Genetics, 14, 1-1.
Skirton, H., Goldsmith, L., Jackson, L., & Tibben, A. (2013). Quality in 
genetic counselling for presymptomatic testing - clinical guidelines 
for practice across the range of genetic conditions. European Journal 
of Human Genetics, 21, 256-260.
Sousa, A. (2006). Epidemiologia Genética da Polineuropatia Amiloidótica 
Familiar [Genetic Epidemiology of Familial Amyloid Polyneuropathy]. 
Sinapse, 6, 74-79.
Tibben, A., Timman, R., Bannink, E., & Duivenvoorden, H. (1997). Three 
years follow-up after presymptomatic testing for Huntington’s Disease 
in tested individuals and partners. Health Psychology, 6, 20-35.
Tibben, A. (2007). Predictive testing for Huntington’s disease. Brain 
Research Bulletin, 72, 165-171.
Timman, R., Roos, R., Maat-Kievit, A., & Tibben, A. (2004). Adverse effects 
of predictive testing for Huntington Disease underestimated: Long-term 
effects 7-10 years after the test. Health Psychology, 23, 189-197.
Weil, J. (2003). Psychosocial genetic counseling in the post-nondirective 
era: A point of view. Journal of Genetic Counseling, 12, 199-211.
Zawacki, T. M., Grace, J., Friedman, J. H., & Sudarsky, L. (2002). 
Executive and emotional dysfunction in Machado-Joseph disease. 
Journal of Movement Disorders, 17, 1004-1010.
